Rational Combos 360
Lead advisors Dr Patrick Hwu, MD Anderson, Dr Axel Hoos, GSK and Dr Ian McCaffery, Janssen, present the 3rd annual Rational Combinations 360° program that addresses business aspects, clinical advancements and scientific data in IO combination strategies to fight a wider range of cancers.
Understanding and determining how to apply certain IO combinations for the right patients and specific tumor types is arguably the most difficult challenge within cancer immunotherapy.
Rational Combinations 360° provides the most up-to-date research, data and progress on combination developments to help IO stakeholders:
- Be at the forefront of the most relevant research and developments for IO combinations from key leadership who are at the pulse of cancer immunotherapy
- Foster collaboration amongst others working in all aspects of cancer immunotherapy by rounding up all stakeholders under one roof
- Receive the latest pre-clinical, translational and clinical data from academia and industry
- Better understand what assets are available for potential combinations that may be able to give patients more treatment options
- Create and prioritize combination strategies targeted toward specific tumor types
- Get key investor and analyst evaluations and insights on the IO combination landscape
- Learn about biomarker advancements, neoantigen approaches and more
- Obtain coverage on a wide range of emerging technologies